|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 早期口腔运动干预对早产儿预后的影响显示文摘目的探讨早期口腔运动干预改善早产儿预后的临床意义。方法选择2015年1月至2017年1月入住聊城市人民医院新生儿重症加强治疗病房(NICU)治疗的早产儿为研究对象。按随机数字表法并经过法定监护人同意将患儿分为干预组和对照组,所有患儿生命体征稳定后均给予常规治疗,干预组在此基础上进行吸吮运动、吞咽功能刺激以及SandraFucile口腔按摩,每日1次,连续14 d;两组均随访6个月。通过进奶5 min时摄入奶量占医嘱奶量百分比(PRO)、喂养效率、喂养进程、非营养性吸吮系统评分(NNS)评价早产儿经口喂养能力;矫正胎龄(PMA)40周时,采用行为神经测定(NBNA)评估新生儿脑发育;生后3月龄、6月龄时,采用婴儿神经系统国际测验量表(Infanib)进行早期运动发育评估。结果最终纳入151例早产儿,其中干预组78例,对照组73例。干预组达完全经口喂养时间明显短于对照组(d:18.1±3.7比23.4±5.8,P<0.05)。与对照组比较,干预组在达到完全经口喂养时PMA较小(周:33.4±0.9比35.9±1.9,P<0.05),喂养效率明显升高(mL/min:10.6±5.1比8.1±4.7,P<0.05),PRO明显增高〔(95±8)%比(72±28)%,P<0.05〕,而体重较轻(g:1836.0±193.0比2000.8±204.5,P<0.05)。干预组和对照组NNS评分均随时间延长逐渐升高(F值分别为86.21、75.23,均P<0.01),且干预组10 d、14 d时NNS评分均显著高于对照组(分:52.89±6.26比46.74±6.24,73.90±7.01比63.53±6.80,均P<0.01)。两组患儿NBNA评分均较低,干预组与对照组比较差异无统计学意义(分:32.7±3.6比32.0±4.1,P>0.05)。患儿3月龄时Infanib评估结果显示,干预组早期运动发育正常的比例明显高于对照组〔67.95%(53/78)比49.31%(36/73),P<0.05〕;6月龄时,干预组早期运动发育正常的比例也明显高于对照组〔84.62%(66/78)比58.90%(43/73),P<0.01〕。结论早期口腔运动干预能够缩短NICU早产儿从管饲喂养到完全经口喂养的过渡时间,改善患儿喂养时的表现。 | 杨春燕 刘凤敏 周丽英 申青华 贾焕荣 许平 李延辉 Stephanie Lee | 2019 | 中华危重病急救医学2019，31，2： | 52 |
| 2 | Mesenchymal stem cells: Molecular characteristics and clinical applications显示文摘Mesenchymal stem cells (MSCs) are non-hematopoietic stem cells with the capacity to differentiate into tissues of both mesenchymal and non-mesenchymal origin. MSCs can differentiate into osteoblastic, chondrogenic, and adipogenic lineages, although recent studies have demonstrated that MSCs are also able to differentiate into other lineages, including neuronal and cardiomyogenic lineages. Since their original isolation from the bone marrow, MSCs have been successfully harvested from many other tissues. Their ease of isolation and ex vivo expansion combined with their immunoprivileged nature has made these cells popular candidates for stem cell therapies. These cells have the potential to alter disease pathophysiology through many modalities including cytokine secretion, capacity to differentiate along various lineages, immune modulation and direct cell-cell interaction with diseased tissue. Here we first review basic features of MSC biology including MSC characteristics in culture, homing mechanisms, differentiation capabilities and immune modulation. We then highlight some in vivo and clinical evidence supporting the therapeutic roles of MSCs and their uses in orthopedic, autoimmune, and ischemic disorders. | Farbod Rastegar Deana Shenaq Eric R Wagner Stephanie H Kim Russell R Reid Hue H Luu Rex C Haydon | 2010 | World Journal of Stem Cells2010，2，4： | 35 |
| 3 | Therapeutic management options for stage Ⅲ non-small cell lung cancer显示文摘Lung cancer is the leading cause of cancer death worldwide.Majority of newly diagnosed lung cancers are non-small cell lung cancer(NSCLC), of which up to half are considered locally advanced at the time of diagnosis.Patients with locally advanced stage Ⅲ NSCLC consists of a heterogeneous population, making management for these patients complex.Surgery has long been the preferred local treatment for patients with resectable disease.For select patients, multimodality therapy involving systemic and radiation therapies in addition to surgery improves treatment outcomes compared to surgery alone.For patients with unresectable disease, concurrent chemoradiation is the preferred treatment.More recently, research into different chemotherapy agents, targeted therapies, radiation fractionation schedules, intensity-modulated radiotherapy, and proton therapy have shown promise to improve treatment outcomes and quality of life.The array of treatment approaches for locally advanced NSCLC is large and constantly evolving.An updated review of past and current literature for the roles of surgery, chemotherapeutic agents, radiation therapy, and targeted therapy for stage Ⅲ NSCLC patients are presented. | Stephanie M Yoon Talha Shaikh Mark Hallman | 2017 | World Journal of Clinical Oncology2017，8，1： | 32 |
| 4 | Methods of vascular control technique during liver resection:a comprehensive review显示文摘BACKGROUND:Significant hemorrhage together with blood transfusion increases postoperative morbidity and mortality of hepatic resection.Hepatic vascular occlusion is effective in minimizing bleeding during hepatic parenchymal transection.This article aimed to review the current role and status of various techniques of hepatic vascular occlusion during hepatic resection.DATA SOURCES:The relevant manuscripts were identified by searching MEDLINE,and PubMed for articles published between January 1980 and April 2010 using the keywords ' vascular control','vascular clamping','vascular exclusion' and 'hepatectomy'.Additional papers were identified by a manual search of the references from the key articles.RESULTS:One randomized controlled trial(RCT) and 5 RCTs showed intermittent Pringle maneuver and ischemic preconditioning followed by continuous Pringle maneuver were superior to continuous Pringle maneuver alone,respectively.Two RCTs compared the outcomes of hepatectomy with and without intermittent Pringle maneuver.One showed Pringle maneuver to be beneficial,while the other failed to show any benefit.One RCT showed that ischemic preconditioning had significantly less blood loss than using intermittent Pringle maneuver.Four RCTs evaluated the use of hemihepatic vascular occlusion.One RCT showed it had significantly less blood loss than Pringle maneuver,while the other 3 showed no significant difference.Only 1 RCT showed it had significantly less liver ischemic injury.No RCT had been carried out to assess segmental vascular occlusion.Two RCTs compared the outcomes of total hepatic vascular exclusion(THVE) and Pringle maneuver.One RCT showed THVE resulted in similar blood loss,but a higher postoperative complication.The other RCT showed less blood loss using THVE but the postoperative complication rate was similar.Both studies showed similar degree of liver ischemic injury.Only one RCT showed that selective hepatic vascular exclusion(SHVE) had less blood loss and liver ischemic injury than Pringle maneuver.CONCLUSION:Due to the great variations in these studies,it is difficult to draw a definitive conclusion on the best technique of hepatic vascular control. | Wan-Yee Lau Eric C.H.Lai Stephanie H.Y.Lau | 2010 | Hepatobiliary & Pancreatic Diseases International2010，9，5： | 27 |
| 5 | Dielectric metasurfaces for complete and independent control of the optical amplitude and phase显示文摘Metasurfaces are optically thin metamaterials that promise complete control of the wavefront of light but are primarily used to control only the phase of light.Here,we present an approach,simple in concept and in practice,that uses meta-atoms with a varying degree of form birefringence and rotation angles to create high-efficiency dielectric metasurfaces that control both the optical amplitude and phase at one or two frequencies.This opens up applications in computer-generated holography,allowing faithful reproduction of both the phase and amplitude of a target holographic scene without the iterative algorithms required in phase-only holography.We demonstrate all-dielectric metasurface holograms with independent and complete control of the amplitude and phase at up to two optical frequencies simultaneously to generate two-and three-dimensional holographic objects.We show that phaseamplitude metasurfaces enable a few features not attainable in phase-only holography;these include creating artifactfree two-dimensional holographic images,encoding phase and amplitude profiles separately at the object plane,encoding intensity profiles at the metasurface and object planes separately,and controlling the surface textures of three-dimensional holographic objects. | Adam C.Overvig Sajan Shrestha Stephanie C.Malek Ming Lu Aaron Stein Changxi Zheng Nanfang Yu | 2019 | Light(Science & Applications)2019，8，1： | 27 |
| 6 | Complications of radiofrequency ablation of hepatic tumors:Frequency and risk factors显示文摘Radiofrequency ablation(RFA)has become an important option in the therapy of primary and secondary hepatic tumors.Surgical resection is still the best treatment option,but only a few of these patients are candidates for surgery:multilobar disease,insufficient liver reserve that will lead to liver failure after resection,extra-hepatic disease,proximity to major bile ducts and vessels,and co-morbidities.RFA has a low mortality and morbidity rate and is considered to be safe.Thus,complications occur and vary widely in the literature.Complications are caused by thermal damage,direct needle injury,infection and the patient’s co-morbidities.Tumor type,type of approach,number of lesions,tumor localization,underlying hepatic disease,the physician’s experience,associated hepatic resection and lesion size have been described as factors significantly associated with complications.The physician in charge should promptly recognize high-risk patients more susceptible to complications,perform a close post procedure follow-up and manage them early and adequately if they occur.We aim to describe complications from RFA of hepatic tumors and their risk factors,as well as a few techniques to avoid them.This way,others can decrease their morbidity rates with better outcomes. | Alexandre Zanchenko Fonseca Stephanie Santin Luiz Guilherme Lisboa Gomes Jaques Waisberg Marcelo Augusto Fontenelle Ribeiro Jr. | 2014 | World Journal of Hepatology2014，6，3： | 24 |
| 7 | The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma:a systematic review显示文摘BACKGROUND:Following curative treatment for hepato-cellular carcinoma(HCC),50%-90% of postoperative death is due to recurrent disease.Intra-hepatic recurrence is frequently the only site of recurrence.Thus,any neoadjuvant or adjuvant therapy,which can decrease or delay the incidence of intra-hepatic recurrence,or any cancer chemoprevention which can prevent a new HCC from developing in the liver remnant,will improve the results of liver resection.This article systematically reviewed the current evidence of neoadjuvant,adjuvant, and chemoprevention in partial hepatectomy of HCC. DATA SOURCES:Studies were identified by searching MEDLINE and PubMed databases for articles from January 1990 to November 2008 using the keywords 'hepatocellular carcinoma','hepatectomy','adjuvant therapy','neoadjuvant therapy',and'regional therapy'. Additional papers and book chapters were identified by a manual search of the references from the key articles. RESULTS:Neoadjuvant transarterial chemoembolization or adjuvant regional transarterial chemotherapy± embolization+systemic chemotherapy did not add benefit. Both adjuvant transarterial radioembolization with 131 I-lipiodol and adjuvant systemic interferon showed promising results.However,there were only a limited number of such studies.CONCLUSIONS:Further randomized controlled studies need to be carried out.Currently,there is no consensus on a standard neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for HCC. | Wan-Yee Lau Eric C.H.Lai Stephanie H.Y.Lau | 2009 | Hepatobiliary & Pancreatic Diseases International2009，8，2： | 24 |
| 8 | Evolving concepts in bone infection: redefining “biofilm”,“acute vs. chronic osteomyelitis”, “the immune proteome” and “local antibiotic therapy”显示文摘Osteomyelitis is a devastating disease caused by microbial infection of bone. While the frequency of infection following elective orthopedic surgery is low, rates of reinfection are disturbingly high. Staphylococcus aureus is responsible for the majority of chronic osteomyelitis cases and is often considered to be incurable due to bacterial persistence deep within bone. Unfortunately, there is no consensus on clinical classifications of osteomyelitis and the ensuing treatment algorithm. Given the high patient morbidity,mortality, and economic burden caused by osteomyelitis, it is important to elucidate mechanisms of bone infection to inform novel strategies for prevention and curative treatment. Recent discoveries in this field have identified three distinct reservoirs of bacterial biofilm including: Staphylococcal abscess communities in the local soft tissue and bone marrow, glycocalyx formation on implant hardware and necrotic tissue, and colonization of the osteocyte-lacuno canalicular network(OLCN) of cortical bone. In contrast, S.aureus intracellular persistence in bone cells has not been substantiated in vivo, which challenges this mode of chronic osteomyelitis. There have also been major advances in our understanding of the immune proteome against S. aureus, from clinical studies of serum antibodies and media enriched for newly synthesized antibodies(MENSA), which may provide new opportunities for osteomyelitis diagnosis, prognosis, and vaccine development. Finally, novel therapies such as antimicrobial implant coatings and antibiotic impregnated 3D-printed scaffolds represent promising strategies for preventing and managing this devastating disease. Here, we review these recent advances and highlight translational opportunities towards a cure. | Elysia A. Masters Ryan P. Trombetta Karen L. de Mesy Bentley Brendan F Boyce Ann Lindley Gill Steven R. Gill Kohei Nishitani Masahiro Ishikawa Yugo Morita Hiromu Ito Sheila N. Bello-Irizarry Mark Ninomiya James D. Brodell Jr. Charles C. Lee Stephanie P. Hao Irvin Oh Chao Xie Hani A. Awad John L. Daiss John R. Owen Stephen L. Kates Edward M. Schwarz Gowrishankar Muthukrishnan | 2019 | Bone Research2019，7，3： | 19 |
| 9 | 外荷载作用下的软黏土电渗试验显示文摘为改善软土地基的固结排水效果,对联合使用电渗固结与预压排水技术进行了电渗试验。对于不同黏土试样,同时施加恒定的75 kPa外荷载和0~20V外电场,研究在耦合作用时的渗透出流变化。试验结果表明:与仅有外荷载作用相比,在耦合作用下表现为阳极渗透出流量减小、阴极渗透出流量增大、总渗透出流量增大;阳极渗透出流量的变化与电压大小无直接关系;耦合作用能提高饱和黏土的排水速率,特别是在外加电压较高时,电渗固结效果较为明显。 | 洪何清 胡黎明 GLENDINNING Stephanie 吴伟令 | 2009 | 清华大学学报(自然科学版)2009，，6： | 18 |
| 10 | Daclatasvir plus asunaprevir in treatment-na?ve patients with hepatitis C virus genotype 1b infection显示文摘AIM To assess daclatasvir plus asunaprevir(d UAL) in treatment-na?ve patients from China's Mainland, Russia and South Korea with hepatitis C virus(HCV) genotype 1 b infection. METHODS Patients were randomly assigned(3:1) to receive 24 wk of treatment with d UAL(daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily) beginning on day 1 of the treatment period(immediate treatment arm) or following 12 wk of matching placebo(placebodeferred treatment arm). The primary endpoint was a comparison of sustained virologic response at posttreatment week 12(SVR12) compared with the historical SVR rate for peg-interferon plus ribavirin(70%) among patients in the immediate treatment arm. The first 12 wk of the study were blinded. Safety was assessed in d UAL-treated patients compared with placebo patients during the first 12 wk(doubleblind phase), and during 24 wk of d UAL in both arms combined.RESULTS In total, 207 patients were randomly assigned to immediate(n = 155) or placebo-deferred(n = 52) treatment. Most patients were Asian(86%), female(59%) and aged < 65 years(90%). Among them, 13% had cirrhosis, 32% had IL28 B non-CC genotypes and 53% had baseline HCV RNA levels of ≥ 6 million IU/m L. Among patients in the immediate treatment arm, SVR12 was achieved by 92%(95% confidence interval: 87.2-96.0), which was significantly higher than the historical comparator rate(70%). SVR12 was largely unaffected by cirrhosis(89%), age ≥ 65 years(92%), male sex(90%), baseline HCV RNA ≥ 6 million(89%) or IL28 B non-CC genotypes(96%), although SVR12 was higher among patients without(96%) than among those with(53%) baseline NS5 A resistanceassociated polymorphisms(at L31 or Y93 H). during the double-blind phase, aminotransferase elevations were more common among placebo recipients than among patients receiving d UAL. during 24 wk of d UAL therapy(combined arms), the most common adverse events(≥ 10%) were elevated alanine aminotransferase and upper respiratory tract infection; emergent grade 3-4 laboratory abnormalities were infrequently observed, and all grade 3-4 aminotransferase abnormalities(alanine aminotransferase, n = 9; aspartate transaminase, n = 6) reversed within 8-11 d. Two patients discontinued d UAL treatment; one due to aminotransferase elevations, nausea, and jaundice and the other due to a fatal adverse event unrelated to treatment. There were no treatment-related deaths.CONCLUSION d UAL was well-tolerated during this phase 3 study, and SVR12 with d UAL treatment(92%) exceeded thehistorical SVR rate for peg-interferon plus ribavirin of 70%. | Lai Wei Fu-Sheng Wang Ming-Xiang Zhang Ji-Dong Jia Alexey A Yakovlev Wen Xie Eduard Burnevich Jun-Qi Niu Yong Jin Jung Xiang-Jun Jiang Min Xu Xin-Yue Chen Qing Xie Jun Li Jin-Lin Hou Hong Tang Xiao-guang Dou Yash Gandhi Wen-Hua Hu Fiona McPhee Stephanie Noviello Michelle Treitel Ling Mo Jun Deng | 2018 | World Journal of Gastroenterology2018，24，12： | 17 |
| 11 | Single Nucleotide Polymorphism Identification in Polyploids: A Review, Example, and Recommendations显示文摘 | Josh Clevenger Carolina Chavarro Stephanie A. Pearl Peggy Ozias-Akins Scott A. Jackson | 2015 | Molecular Plant2015，8，6： | 16 |
| 12 | Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development显示文摘BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy(ALPPS) has recently been developed to induce rapid liver hypertrophy and reduce posthepatectomy liver failure in patients with insufficient future liver remnant(FLR). ALPPS is still considered to be in an early developmental phase because surgical indications and techniques have not been standardized. This article aimed to review the current role and future developments of ALPPS.DATA SOURCES: Studies were identified by searching MEDLINE and Pub Med for articles from January 2007 to October 2016 using the keywords 'associating liver partition and portal vein ligation for staged hepatectomy' and 'ALPPS'. Additional papers were identified by a manual search of references from key articles.RESULTS: ALPPS induces more hypertrophy of the FLR in less time than portal vein embolization or portal vein ligation.The benefits of ALPPS include rapid hypertrophy 47%-110% of the liver over a median of 6-16.4 days, and 95%-100% completion rate of the second stage of ALPPS. The main criticisms of ALPPS are centered on its high morbidity and mortality rates. Morbidity rates after ALPPS have been reported to be 15.3%-100%, with ≥ the Clavien-Dindo grade III morbidity of 13.6%-44%. Mortality rates have been reported to be 0%-29%.The important questions to ask even if oncologic long-term results are acceptable are: whether the gain in quality and quantity of life can be off balance by the substantial risks of morbidity and mortality, and whether stimulation of rapid liver hypertrophy also accelerates rapid tumor progression and spread. Up till now, the documentations of the ALPPS procedure come mainly from case series, and most of these series include heterogeneous groups of malignancies. The numbers are also too small to separately evaluate survival for different tumor etiologies.CONCLUSIONS: Currently, knowledge on ALPPS is limited, and prospective randomized studies are lacking. From the reported preliminary results, safety of the ALPPS procedure remains questionable. ALPPS should only be used in experienced, high-volume hepatobiliary centers. | Wan Yee Lau Eric CH Lai Stephanie HY Lau | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，1： | 16 |
| 13 | Aberrant expression of enzymes regulating m^6A mRNA methylation: implication in cancer显示文摘N^6-methyladenosine(m^6 A) is an essential RNA modification that regulates key cellular processes, including stem cell renewal,cellular differentiation, and response to DNA damage. Unsurprisingly, aberrant m^6 A methylation has been implicated in the development and maintenance of diverse human cancers. Altered m^6 A levels affect RNA processing, mRNA degradation, and translation of mRNAs into proteins, thereby disrupting gene expression regulation and promoting tumorigenesis. Recent studies have reported that the abnormal expression of m^6 A regulatory enzymes affects m^6 A abundance and consequently dysregulates the expression of tumor suppressor genes and oncogenes, including MYC, SOCS2, ADAM19, and PTEN. In this review, we discuss the specific roles of m^6 A missing space 'writers', 'erasers', and 'readers' in normal physiology and how their altered expression promotes tumorigenesis. We also describe the potential of exploiting the aberrant expression of these enzymes for cancer diagnosis, prognosis, and the development of novel therapies. | Natalia Pinello Stephanie Sun Justin Jong-Leong Wong | 2018 | Cancer Biology & Medicine2018，15，4： | 15 |
| 14 | Co-expression of CDX2 and MUC2 in gastric carcinomas: Correlations with clinico-pathological parameters and prognosis显示文摘AIM: To evaluate the role of CDX2 homeobox protein as a predictor for cancer progression and prognosis as well as its correlation with MUC2 expression. CDX2 represents a transcription factor for various intestinal genes (including MUC2) and thus an important regulator of intestinal differentiation, which could previously be identified in gastric carcinomas and intestinal metaplasia.METHODS: Formalin-fixed and paraffin-embedded tissues from 190 gastric carcinoma patients were stained with monodonal antibodies recognizing CDX2 and MUC2, respectively. Immunoreactivity was evaluated semiquantitatively and statistical analyses including χ2 tests, uni- and multi-variate survival analyses were performed.RESULTS: CDX2 was mostly expressed in a nuclear or supranuclear pattern, whereas MUC2 showed an almost exclusive supranuclear reactivity. Both antigens were present in >80% of areas exhibiting intestinal metaplasia. An immunoreactivity in >5% of the tumor area was observed in 57% (CDX2) or in 21% (MUC2) of the carcinomas. The presence of both molecules did not correlate with WHO,significantly stronger vlUC2 expression in mucinous tumors). CDX2 correlated with a lower pT and pN stage in the subgroups of intestinal and stage I cancers and was associated with MUC2 positivity. A prognostic impact of CDX2 or MUC2 was not observed. CONCLUSION: CDX2 and MUC2 play an important role in the differentiation of normal, inflamed, and neoplastic gastric tissues. According to our results, loss of CDX2 may represent a marker of tumor progression in early gastric cancer and carcinomas with an intestinal phenotype. | Kristina Roessler Stefan P.M(o|¨)nig Paul M.Schneider Franz-Georg Hanisch Stephanie Landsberg Juergen Thiele Arnulf H.H(o|¨)lscher Hans P.Dienes Stephan E.Baldus | 2005 | World Journal of Gastroenterology2005，11，21： | 15 |
| 15 | Dynal磁珠富集大熊猫微卫星标记显示文摘应用Dynal磁珠生物素标记的微卫星探针与大熊猫基因组酶切片段杂交,捕获400~600bp含有微卫星序列的DNA片段,连接到pGEM T载体中,构建富集微卫星序列的小片段插入文库。应用γ32P标记的探针筛选文库,从2880个转化子中获得了260个阳性克隆。对54个序列进行了测序,并成功地设计了大熊猫微卫星引物37对。该方法能有效提高筛选微卫星标记的效率。 | 沈富军 Phill Watts 张志和 张安居 Stephanie Sanderson SteveJ.Kemp 岳碧松 | 2005 | Acta Genetica Sinica2005，32，5： | 14 |
| 16 | Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-κB activation显示文摘AIM: Different strains of bifidobacteria were analysed for their effects on HT-29 intestinal epithelial cells (IECs) in in vitro models both of the non-inflamed and inflamed intestinal epithelium. METHODS: A reporter gene system in HT-29 cells was used to measure levels of NF-KB activation after challenge with bifidobacteria or after bacterial pre-treatment following LPS challenge. IL-8 protein and pro-inflammatory gene expression was investigated using normal HT-29 cells. RESULTS: None of the bifidobacteria tested induced activation of nuclear factor KB (NF-KB) indicating that bifidobacteria themselves do not induce inflammatory events in IECs. However, six out of eight bifidobacteria tested inhibited lipopolysaccharide- (LPS-) induced NFKB activation in a dose- and strain-dependent manner. In contrast, NF-KB activation in response to challenge with tumor necrosis factor-α(TNF-α) was affected by none of the tested bifidobacteria, indicating that the inhibitory effect of bifidobacteria is specific for LPS-induced inflammation in IECs. As shown with two of the six inhibitionpositive bifidobacteria, LPS-induced inhibition of NFKB activation was accompanied by a dose-dependent decrease of interleukin 8 (IL-8) secretion and by lower mRNA levels for IL-8, TNF-a, cyclooxygenase 2 (Cox-2), and intercellular adhesion molecule 1 (ICAM-1). CONCLUSION: Some strains of bifidobacteria are effective in inhibiting LPS-induced inflammation and thus might be appropriate candidates for probiotic intervention in chronic intestinal inflammation. | Christian U Riedel Francis Foata David Philippe Oskar Adolfsson Bernhard J Eikmanns Stephanie Blum | 2006 | World Journal of Gastroenterology2006，12，23： | 14 |
| 17 | Obesity: modern man's fertility nemesis显示文摘肥胖流行成长了到有关最近的年里,不是仅仅在西方的世界上的比例,但是在也开发国家。在男富饶和肥沃的相应减少可以向肥胖在平行被解释,并且肥胖应该被看作男富饶的病原学。研究证明肥胖由减少精液质量贡献不孕,改变精子 proteomes,贡献可勃起的机能障碍,并且导致与肥胖有关的另外的物理问题。为在男不孕上解释肥胖的效果的机制包括睡觉呼吸暂停和增加的阴囊的温度包括反常繁殖荷尔蒙层次,与肥胖联系的脂肪质导出荷尔蒙和 adipokines 的一个增加的版本,和另外的物理问题。最近,为肥胖相关的不孕的基因因素和标记被发现了并且可以解释肥沃的肥胖、不肥沃的肥胖的人之间的差别。处理为与肥胖有关的不孕是可得到的不仅,而且作为为从肥胖产生的另外的 comorbidities 的一个处理。自然重量损失,以及 bariatric 外科是为肥胖的病人的选择并且在恢复富饶和正常神经质的侧面显示出有希望的结果。脂肪质导出荷尔蒙的治疗学的干预包括 aromatase 禁止者,外长的睾丸激素代替治疗和维护和规定,特别地 leptin,可能也能在肥胖的男性恢复富饶。因为在这个区域的研究的相对不知道和缺乏,控制了研究应该被承担,更多的焦点应该作为男不孕的 etiolgy 被给肥胖。 | Stephanie Cabler Ashok Agarwal Margot Flint Stefan S. Du Plessis | 2010 | Asian Journal of Andrology2010，12，4： | 14 |
| 18 | Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration显示文摘嗜中性的渗入是含酒精的 steatohepatitis 的一个特点;然而,内在的机制仍然保持不清楚。我们以前报导 synergistically 喂的 chronic-plus-binge 乙醇导致 neutrophils 的肝的招募,它贡献肝损害。在这份报纸,我们在 chronic-plus-binge 乙醇喂导致调查了不变的自然漂亮 T (iNKT ) 房间的角色肝的嗜中性的渗入和肝损害。野类型并且 iNKT 的二紧张房间缺乏的老鼠(CD1d 缺乏并且 Jα 18-deficient 老鼠) 受到喂的 chronic-plus-binge 乙醇。肝损害和发炎被检验。synergistically 喂的 Chronic-plus-binge 乙醇增加了肝的 iNKT 房间的数字并且导致了他们的激活,与独自的长期的喂或饮酒作乐相比。iNKT 房间缺乏的老鼠被保护免受 chronic-plus-binge 的伤害导致乙醇的肝的嗜中性的渗入和肝损害。而且,显著地喂几基因的肝的表示在野类型的老鼠与发炎和嗜中性的招募联系了的 upregulated 的 chronic-plus-binge 乙醇,而是这些基因的正式就职在 iNKT 被废除房间缺乏的老鼠。重要地,几 cytokines 和 chemokines (例如, MIP-2, MIP-1, IL-4, IL-6 和 osteopontin ) 在嗜中性的渗入包含了在肝的 NKT 房间的 upregulated 从 chronic-plus-binge 被孤立与喂对的老鼠相比的喂乙醇的老鼠。最后,有堵住抗体的 CD1d 的处理,堵住 iNKT 房间激活,部分阻止了 chronic-plus-binge 导致乙醇的肝损害和发炎。喂的 Chronic-plus-binge 乙醇激活肝的 iNKT 房间,它在早含酒精的肝损害的发展起一个关键作用,部分地由释放招募的调停人 neutrophils 到肝,并且这样, iNKT 房间为含酒精的肝的治疗代表一个潜在的治疗学的目标疾病。 | Stephanie Mathews Dechun Feng Igor Maricic Cynthia Ju Vipin Kumar Bin Gao | 2016 | Cellular & Molecular Immunology2016，13，2： | 14 |
| 19 | Cooling dialysate during in-center hemodialysis:Beneficial and deleterious effects显示文摘The use of cooled dialysate temperatures first came about in the early 1980 s as a way to curb the incidence of intradialytic hypotension(IDH). IDH was then, and it remains today, the most common complication affecting chronic hemodialysis patients. It decreases quality of life on dialysis and is an independent risk factor for mortality. Cooling dialysate was first employed as a technique to incite peripheral vasoconstriction on dialysis and in turn reduce the incidence of intradialytic hypotension. Although it has become a common practice amongst incenter hemodialysis units, cooled dialysate results in up to 70% of patients feeling cold while on dialysis and some even experience shivering. Over the years, various studies have been performed to evaluate the safety and efficacy of cooled dialysate in comparison to a standard, more thermoneutral dialysate temperature of 37 ℃. Although these studies are limited by small sample size, they are promising in many aspects. They demonstrated that cooled dialysis is safe and equally efficacious as thermoneutral dialysis. Although patients report feeling cold on dialysis, they also report increased energy and an improvement in their overall health following cooled dialysis. They established that cooling dialysate temperatures improves hemodynamic tolerability during and after hemodialysis, even in patients prone to IDH, and does so without adversely affecting dialysis adequacy. Cooled dialysis also reduces the incidence of IDH and has a protective effect over major organs including the heart and brain. Finally, it is an inexpensive measure that decreases economic burden by reducing necessary nursing intervention for issues that arise on hemodialysis such as IDH. Before cooled dialysate becomes standard of care for patients on chronic hemodialysis, larger studies with longer follow-up periods will need to take place to confirm the encouraging outcomes mentioned here. | Stephanie M Toth-Manikowski Stephen M Sozio | 2016 | World Journal of Nephrology2016，5，2： | 14 |
| 20 | Sleep disorders and chronic kidney disease显示文摘Sleep disorders have a profound and well-documented impact on overall health and quality of life in the general population. In patients with chronic disease, sleep disorders are more prevalent, with an additional morbidity and mortality burden. The complex and dynamic relationship between sleep disorders and chronic kidney disease(CKD) remain relatively little investigated. This article presents an overview of sleep disorders in patients with CKD, with emphasis on relevant pathophysiologic underpinnings and clinical presentations. Evidence-based interventions will be discussed, in the context of individual sleep disorders, namely sleep apnea, insomnia, restless leg syndrome and excessive daytime sleepiness. Limitations of the current knowledge as well as future research directions will be highlighted, with a final discussion of different conceptual frameworks of the relationship between sleep disorders and CKD. | Stephanie C Maung Ammar El Sara Cherylle Chapman Danielle Cohen Daniel Cukor | 2016 | World Journal of Nephrology2016，5，3： | 13 |
您所在的机构暂未开通此部分的功能，请联系管理员